Objectives-Liver biopsy remains the reference standard for the assessment of liver fibrosis, but this procedure is invasive and can lead to complications. Thus, studies to determine the optimal noninvasive test are warranted. This study compared several noninvasive tests and their combinations for evaluating liver fibrosis stages in patients with chronic hepatitis B.
incidence zone of HBV infection, with an HBV infection rate of 7.18% (93 million). 2 Knowledge of the liver fibrosis stage can guide the treatment of chronic hepatitis B. The important levels are fibrosis stages F2 and higher and F4. For continuously HBV DNA-positive patients who will not accept standard antiviral treatment, if there is the presence of liver fibrosis worse than F2, antiviral treatment should be considered; if there is the presence of F4, antiviral treatment must not be withheld. 3 Therefore, it is important to estimate precisely the degree of liver fibrosis. Although percutaneous liver biopsy is the reference standard for the diagnosis of liver fibrosis, 4 this method is complex. Most patients receiving liver biopsy must be hospitalized, and complications, including pain, intraabdominal hemorrhage, infection, biliary leakage, hemothorax, and pneumothorax, have occurred. 5, 6 The mortality rate of liver biopsy is 0.05%. 7 Sampling errors and intraobserver and interobserver variations decrease the accuracy of pathologic diagnosis, 8, 9 and some patients refuse to undergo liver biopsy. Thus, the clinical application of liver biopsy is problematic. 10 Currently, noninvasive tests for assessing liver fibrosis mainly consist of elastography and the use of serum indices. With regard to elastography, transient elastography (FibroScan) and acoustic radiation force impulse (ARFI) are mostly applied for the diagnosis of liver fibrosis. FibroScan is a 1-dimensional transient elastographic method developed by the French company Echosens (Paris, France). The low frequency (50 Hz) and amplitude pulse from the probe vibrator toward the tissue induce an elastic shear wave propagating through the tissue. The elastic shear wave velocity (SWV) is related to the tissue stiffness (E 5 3 q V
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, where E is elasticity; V is SWV; and q is mass density), and the system automatically records successful test results, generally measuring 10 times and calculating the median, expressed in kilopascals. However, FibroScan is of limited use in patients with obesity, intercostal space stenosis, and ascites. 11 Acoustic radiation force impulse is a unique elasticity imaging technology produced by the ACUSON S2000 color Doppler diagnostic ultrasound equipment (Siemens AG, Munich, Germany). It transmits short focused acoustic pulses with a frequency of 2.67 MHz through transducers and generates localized displacement, which leads to shear wave propagation in tissue. The SWV is mathematically positively related to the tissue elasticity and can noninvasively and quantitatively assess liver tissue stiffness, expressed in meters per second; ARFI can be applied for patients with obesity or ascites. 12 Recent studies have affirmed that the SWV, aspartate aminotransaminase-to-platelet ratio index (APRI), and fibrosis-4 index (FIB-4) have positive significance in predicting the liver fibrosis stage of viral hepatitis B or C. [13] [14] [15] [16] [17] Currently, only a few studies have compared the value of the SWV, APRI, and FIB-4 in the diagnosis of liver fibrosis caused by chronic hepatitis C or B 18, 19 ; therefore, it is a dilemma for physicians to select the best tests among the SWV, APRI, FIB-4, aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), and their combinations. This retrospective study aimed to analyze the values of the SWV, APRI, FIB-4, AAR, and their combinations in predicting the stage of liver fibrosis caused by chronic hepatitis B.
Materials and Methods

Study Population
This retrospective study was approved by the Institutional Ethics Committee. A total of 174 inpatients with chronic hepatitis B were enrolled in the Department of Infectious Disease of Baoji Central Hospital from May 2011 to November 2014. Patients were included in this study if their serum hepatitis B surface antigen result was positive for longer than 6 months, if they had persistent or intermittent elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), or if liver biopsy, ARFI, and serum tests were performed to evaluate liver histopathologic changes.
Patients with underlying diseases, such as non-B hepatitis, coinfection with other viruses, autoimmune hepatitis, alcoholic liver disease, primary biliary hepatitis, fatty liver, liver congestion, and massive ascites, as well as patients with SWV measurement failure and patients taking drugs such as aspirin, warfarin, and heparin, were excluded from the study. For all of the examinations and tests, informed consent was obtained from the patients and their families.
Measurement of the Liver SWV All of liver SWV measurements were obtained before liver biopsy by the ARFI technique implemented on the ACUSON S2000 system by a radiologist with at least 3 months of experience in ARFI elastography. The patients were placed in the left lateral decubitus position, and their right hand was raised onto their head. A region of interest in anterior right hepatic lobe segment VIII was chosen. The image was enlarged and showed an area distant from the intrahepatic vessels and bile ducts. The detection depth remained 3 to 4 cm from the body surface and 1.5 to 2 cm from the liver capsule, and the patients were also reminded to hold their breath at the end of inspiration during testing. The same area was measured 10 times for each patient, and the median value was calculated and reported in meters per second.
Serum Fibrosis Algorithms
The following blood parameters were collected (in the same laboratory) for all of the patients within the same week as the liver biopsy and ARFI tests: AST levels, ALT levels, and platelet count. The upper limit of normal of ALT and AST was considered 40 IU/mL. The normal range for platelets was considered 100 to 300 3 10 
Liver Biopsy and Histologic Analysis
Liver biopsy was conducted under ultrasound guidance after the ARFI examination using an 18-gauge, 20-cmlong needle and the suction technique. The puncture site was located at the area of the ARFI examination. The puncture path avoided the main intrahepatic vessels. Sampling was conducted 2 to 3 times, and the lengths of the tissue strips obtained were greater than 1.5 cm.
All of the tissue samples were fixed in formalin and then were embedded in paraffin; the samples were then serially sectioned and stained with Masson, reticulin, and hematoxylin-eosin. The samples were examined by an associate chief pathologist who had 5 years of experience in evaluating liver fibrosis stages. Liver fibrosis stages were evaluated by the METAVIR scoring system on a 5-point scale as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with a few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. 22 Liver inflammation grades were scored on scale according to the portal tract and periportal, lobular inflammation as follows: G0, absence; G1, portal inflammation, degeneration, and a few spotty focal areas of necrosis; G2, mild piecemeal necrosis, degeneration, spotty focal necrosis, or acidophilic bodies; G3, moderate piecemeal necrosis, degeneration, confluent necrosis, or bridging necrosis; and G4, severe piecemeal necrosis, widely bridging necrosis, involving multiple lobules (multiplelobule necrosis). 23 
Statistical Analysis
The data were analyzed with SPSS version 13.0 software (IBM Corporation, Armonk, NY) and MedCalc version 15.2.1 software (MedCalc, Ostend, Belgium). Correlations between noninvasive tests and the histological fibrosis stage were assessed by the Spearman test. To generate predictive probability as an index of combined tests, binary logistic regression analyses were performed. The diagnostic performance of the SWV, APRI, FIB-4, AAR, and combined tests was assessed by receiver operating characteristic curves. P < .05 was considered statistically significant. Cutoff values were defined by the Youden index, which maximized the sum of the sensitivities and specificities in predicting individual stages. The sensitivity, specificity, positive predictive value, negative 
Results
Patient Characteristics
The patients included 107 men and 67 women with a mean age 6 SD of 36. than the upper level of normal was 73.0% (127 cases). The percentage of platelet levels less than the lower level of normal was 26.4% (46 cases).
Correlation Analysis
The SWV, APRI, and FIB-4 were positively correlated with the pathologic liver fibrosis stage. The SWV had the strongest correlation with the liver fibrosis stage, followed by the APRI. The FIB-4 was weakly correlated with the liver fibrosis stage. The AAR had no obvious correlation with the liver fibrosis stage ( Table 2 and Figures 1-4) .
Comparison of Noninvasive Tests of Different HBeAg Statuses and Inflammation Grades Regarding the Fibrosis Stage F2
This study had few cases in other stages except F2 after the grouping between different HBeAg statuses and inflammation grades. Patients with F2 were divided into 2 groups according to HBeAg status: HBeAg positive and HBeAg negative. Differences in the SWV, APRI, FIB4, and AAR between the groups were not statistically significant. Similarly, patients with F2 were divided into 2 groups according to the inflammation grade: mild inflammation (G <2) and moderate or severe inflammation (G 2). Differences in the SWV, APRI, FIB-4, and AAR between the groups were not statistically significant ( Table 3) .
Comparison of the Efficacy of the SWV, APRI, FIB-4, and AAR in Diagnosing the Liver Fibrosis Stage
The optimal cutoff values, sensitivities, specificities, positive predictive values, negative predictive values, positive likelihood ratios, and negative likelihood ratios are shown in Table 4 . The SWV and APRI were best at diagnosing substantial liver fibrosis (F2), followed by the FIB-4 (SWV-FIB-4, P < .001; APRI-FIB-4, P 5 .006). The AAR (AUC 5 0.47; P 5 .462) was unsuitable for diagnosis ( Figure 5 ). The optimal cutoff values of the SWV and APRI were 1.41 m/s and 0.81, respectively. The SWV was the best test for assessing cirrhosis (F4), followed by the APRI (SWV-APRI, P < .001) and FIB-4 (SWV-FIB-4, P < .001). The AAR (AUC 5 0.45; P 5 .527) was unsuitable for diagnosis ( Figure 6 ). The optimal cutoff value of the SWV was 1.74 m/s.
Combined Diagnosis of Liver Fibrosis With Noninvasive Indicators
A logistic regression analysis was applied to develop a probability function, which was used as an aggregative indicator for the evaluation of liver fibrosis. The AUC of ARFI combined with the APRI for use in the diagnosis of substantial liver fibrosis was greater than that of the SWV alone (P 5 .014). Additionally, the sensitivity and negative predictive value were improved with the combination. Acoustic radiation force impulse combined with the FIB-4 failed to improve the efficacy of assessment of substantial liver fibrosis. The AUC of ARFI combined with the APRI and AUC of ARFI combined with the FIB-4 for assessing cirrhosis were both comparable with the use of SWV alone. However, ARFI combined with the APRI improved the sensitivity (Table 4) .
Discussion
Substantial liver fibrosis with hepatitis B is an important guideline for conducting antiviral therapy. Cirrhosis is irreversible; therefore, it suggests a poor prognosis. Although liver biopsy is the current reference standard for the diagnosis of liver fibrosis, it remains problematic. Consequently, researchers have focused on exploring noninvasive techniques, mainly including the use of serum indicators and elastography. This study retrospectively analyzed the value of ARFI, the APRI, the FIB-4, the AAR, and their combinations for the diagnosis of liver fibrosis.
Acoustic radiation force impulse imaging is a novel and nondamaging technique that is used for evaluating tissue stiffness, and it is different from traditional techniques in that ARFI can be used to evaluate elasticity in deep tissues without external pressure. Therefore, ARFI has been applied not only in liver assessment but also in assessing the spleen, pancreas, kidney, prostate, and other organs. 24 It offers many advantages, including operational convenience, low expense, the absence of a need for radiation, and guidance by 2-dimensional images. Recently, a prospective study revealed that the AUC of ARFI for substantial liver fibrosis was 0.75, and that for cirrhosis was 0.96. 25 This study of 174 patients with HBV demonstrated that the AUCs of the SWV for the diagnosis of substantial liver fibrosis and cirrhosis were similar. The AUC for evaluating substantial liver fibrosis in this study might have been smaller than that found in a prior prospective study, perhaps because of the different body mass indices of the study population, which came from Asia in this study and from Europe in the prior study. However, the AUC for detecting cirrhosis in this study was equal to that found in the prior prospective study. Cirrhosis was a predictor of concordance between liver biopsy and the SWV acquired from ARFI. 26 Therefore, ARFI predicted cirrhosis in different studies with good consistency. A previous retrospective study of hepatitis C showed that the AUC of the SWV in the diagnosis of substantial liver fibrosis was 0.79, consistent with this study. It was 0.79 for evaluating cirrhosis, which was smaller than in this study. 27 Serum fibrosis algorithms, including the APRI, FIB-4, and AAR, are common serologic tests for assessing liver fibrosis: the involved blood markers are routinely inspected in patients with chronic hepatitis B; they have a low cost; and they are easily accessed. Xiao et al 28 performed a meta-analysis of the use of the APRI and FIB-4 for detecting liver fibrosis in hepatitis B, and they reported that the APRI and FIB-4 had moderate Data are presented as mean 6 SD where applicable. sensitivity and accuracy and were not significantly different when evaluating substantial liver fibrosis (AUC 5 0.74 versus 0.78). The corresponding sensitivity and specificity of the APRI and FIB-4 for detecting liver fibrosis in hepatitis B were 70.0% and 65.4% and 60.0%
and 73.6%, respectively. This study revealed that the APRI was better than the FIB-4 for assessing substantial liver fibrosis. Moreover, Xiao et al 28 found that the FIB-4 was better than the APRI (AUC 5 0.84 versus 0.73) for evaluating cirrhosis. However, this study found that the APRI and FIB-4 were not significantly different when used for evaluating cirrhosis, but the AUC values were smaller than those found by Xiao et al. 28 We found that the AAR was not significantly correlated with liver the fibrosis stage. Eminler et al 16 found that there was no significant relationship between the degree of hepatic fibrosis and the AAR score in patients with hepatitis B or C; thus, the AAR had little value for predicting liver fibrosis in chronic hepatitis B.
Silva Junior et al 18 performed a prospective study comparing the use of ARFI, the FIB-4, and the Forns and Kings scores in hepatitis C and found that the ARFI was more useful than other serum indicators for predicting liver fibrosis and cirrhosis. However, in this study, ARFI was equally as useful as the APRI and was more useful than the FIB-4 for assessing substantial liver fibrosis in hepatitis B. The cutoff value of SWV for evaluating cirrhosis was 1.74 m/s, and the results indicated that when the SWV was less than 1.74 m/s, only 0.7% of patients without cirrhosis had a misdiagnosis of cirrhosis. The probability of a definite diagnosis was 11.21 times greater than that of misdiagnosis. The SWV performed excellently in the diagnosis of cirrhosis and might be an acceptable substitute for liver biopsy.
The data regarding liver fibrosis stage in patients with negative HBeAg results were insufficient. Wang et al 29 established a model for predicting the liver fibrosis stage in patients with negative e-antigen results using routine parameters that could accurately predict both substantial fibrosis and cirrhosis. Our findings were that the SWV, APRI, FIB-4, and AAR in patients with F2 did not significantly differ between the negative and positive HBeAg groups. Furthermore, among patients with F2, differences in the SWV APRI, FIB-4, and AAR among patients with different inflammation grades were not statistically significant, indicating that the inflammation grade had no effect on the accuracy of ARFI for predicting liver fibrosis. These results contradicted the findings of Dong et al, 30 possibly because of the small number of patients.
The SWV was of moderate value in the diagnosis of substantial liver fibrosis and thus cannot be substituted for liver biopsy. Therefore, researchers have focused on the use of the SWV combined with serum indicators. Stibbe et al 31 showed that a combination of tests (transient elastography, hyaluronic acid, and FibroTest [Assistance Publique-Hôpitaux de Paris, Paris, France]) increased the AUC statistically. The SWV combined with the APRI also improved the efficacy of diagnosis of substantial liver fibrosis in this study, and an additional 20.6% of patients with substantial liver fibrosis were detected. The SWV combined with the APRI enabled 16.9% of cases to avoid liver biopsy.
The limitations of this study were as follows. First, the number of samples was small. The performance of ARFI, the APRI, the FIB-4, and the AAR for detecting liver fibrosis in hepatitis B should be confirmed with a larger number of patients. Second, this retrospective study was not able to integrally collect all of the data used in the Forns and King models. Hence, we failed to compare ARFI and the Forns and King models for diagnosing liver fibrosis in hepatitis B.
In conclusion, ARFI and the APRI were equally good for detecting substantial liver fibrosis, followed by the FIB-4. Acoustic radiation force impulse imaging was superior to the APRI and FIB-4 for assessing cirrhosis. Acoustic radiation force impulse imaging combined with the APRI might improve the efficacy of evaluating substantial liver fibrosis. The HBeAg status and inflammation grade did not affect the accuracy of ARFI, the APRI, or the FIB-4 for predicting the liver fibrosis stage.
